Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography

Background:Magnetic resonance elastography (MRE) is an emerging imaging technique that affords non-invasive quantitative assessment and visualization of tissue mechanical properties in vivo.Methods:In this study, MRE was used to quantify (kPa) the absolute value of the complex shear modulus |G*|, elasticity Gd and viscosity Gl of SW620 human colorectal cancer xenografts before and 24 h after treatment with either 200 mg kg−1 of the vascular disrupting agent ZD6126 (N-acetylcolchinol-O-phosphate) or vehicle control, and the data were compared with changes in water diffusivity measured by diffusion-weighted magnetic resonance imaging.Results:A heterogeneous distribution of |G*|, Gd and Gl was observed pre-treatment with an intertumoral coefficient of variation of 13% for |G*|. There were no significant changes in the vehicle-treated cohort. In contrast, ZD6126 induced a significant decrease in the tumour-averaged |G*| (P<0.01), Gd (P<0.01) and Gl (P<0.05), and this was associated with histologically confirmed central necrosis. This reduction in tumour viscoelasticity occurred at a time when no significant change in tumour apparent diffusion coefficient (ADC) was observed.Conclusions:These data demonstrate that MRE can provide early imaging biomarkers for treatment-induced tumour necrosis.

[1]  Septimiu E. Salcudean,et al.  Transperineal prostate MR elastography: Initial in vivo results , 2013, Magnetic resonance in medicine.

[2]  Chryso Kanthou,et al.  Disrupting tumour blood vessels , 2005, Nature Reviews Cancer.

[3]  John C Waterton,et al.  Qualification of imaging biomarkers for oncology drug development. , 2012, European journal of cancer.

[4]  Kristian Pietras,et al.  High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.

[5]  F. Schaefer,et al.  EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography. Part 1: Basic Principles and Technology , 2013, Ultraschall in der Medizin.

[6]  V. Vilgrain,et al.  MR elastography of liver tumours: value of viscoelastic properties for tumour characterisation , 2012, European Radiology.

[7]  J. Waterton,et al.  Translational Magnetic Resonance Imaging and Spectroscopy: Opportunities and Challenges , 2013 .

[8]  F. Westwood,et al.  Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  S. Walker-Samuel,et al.  The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function , 2012, British Journal of Cancer.

[10]  P. Choyke,et al.  Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.

[11]  R. Sinkus,et al.  High-resolution tensor MR elastography for breast tumour detection. , 2000, Physics in medicine and biology.

[12]  Mickael Tanter,et al.  MR elastography of breast lesions: Understanding the solid/liquid duality can improve the specificity of contrast‐enhanced MR mammography , 2007, Magnetic resonance in medicine.

[13]  D. Blakey,et al.  ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. , 2002, Cancer research.

[14]  H. Dvorak,et al.  Tumor microenvironment and progression , 2011, Journal of surgical oncology.

[15]  M. Horsman,et al.  Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. , 2006, Cancer research.

[16]  J. Waterton CHAPTER 12:Translational Magnetic Resonance Imaging and Spectroscopy: Opportunities and Challenges , 2013 .

[17]  Ralph Sinkus,et al.  Colon tumor growth and antivascular treatment in mice: complementary assessment with MR elastography and diffusion-weighted MR imaging. , 2012, Radiology.

[18]  J. Waterton,et al.  False-negative MRI biomarkers of tumour response to targeted cancer therapeutics , 2012, British Journal of Cancer.

[19]  J. Griffiths,et al.  Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126. , 2006, Microvascular research.

[20]  R Sinkus,et al.  MR elastography of the breast:preliminary clinical results. , 2002, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[21]  Martin O. Leach,et al.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial , 2009, European Radiology.

[22]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[23]  D. Yeung,et al.  MR elastography of the head and neck: driver design and initial results. , 2013, Magnetic resonance imaging.

[24]  Richard L Ehman,et al.  MR elastography derived shear stiffness—a new imaging biomarker for the assessment of early tumor response to chemotherapy , 2014, Magnetic resonance in medicine.

[25]  Simon Walker-Samuel,et al.  Improving apparent diffusion coefficient estimates and elucidating tumor heterogeneity using Bayesian adaptive smoothing , 2011, Magnetic resonance in medicine.

[26]  Mark J. Ratain,et al.  Measuring response in a post-RECIST world: from black and white to shades of grey , 2006, Nature Reviews Cancer.

[27]  Cynthia A. Reinhart-King,et al.  Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.

[28]  R. Ehman,et al.  Magnetic resonance elastography , 1996, Nature Medicine.

[29]  Barjor Gimi,et al.  Diffusion-weighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126 , 2007, Cancer biology & therapy.

[30]  Ralph Sinkus,et al.  Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. , 2012, European journal of cancer.

[31]  Ralph Sinkus,et al.  Diagnostic value of MR elastography in addition to contrast-enhanced MR imaging of the breast—initial clinical results , 2010, European Radiology.

[32]  F. Westwood,et al.  ZD6126: a novel small molecule vascular targeting agent. , 2002, International journal of radiation oncology, biology, physics.